Combogesic – Medicinal Product Register of Latvia

Paracetamolum, Ibuprofenum

Search by the name of the active substance

Return to the results

Medicinal product name

Combogesic 500 mg/150 mg film-coated tablets

Pharmaceutical form

Film-coated tablet

Strength

500 mg/150 mg

Information from the MAH on shortages

No information on expected shortages

Availability of medicinal product

Product No.	Package size	Wholesalers' stock state
15-0014-02	N10	Is available

Legal status

OTC OTC

Package leaflet

13-04-2023

Summary of product characteristics

13-04-2023

ATC code

N02BE51 – Analgesics

Information for Marketing authorisation holders

View

Product information leaflet and summary of product characteristics in MS Word format.

Package leaflet	13-04-2023
Summary of product characteristics	13-04-2023

Medicinal products (7)

Display only medicinal products with a declared price

Display only medicinal products available in wholesalers' stock

Availability of medicinal product	Wholesalers	Package size, content	Primary packaging	Maximum admissible pharmacy price (€ incl. VAT)	Product No.	Labelling
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N8 (500 mg/150 mg)	PVC/Al blister		15-0014-01	Labelling text Aug 15, 2019
Is available (according to the information provided by wholesalers) (3531 containers)	Tamro, Recipe Plus, Magnum Medical, Euroaptieka, Oribalt Rīga, Jelgavfarm	N10 (500 mg/150 mg)	PVC/Al blister	€ 5.66	15-0014-02	Labelling text Aug 15, 2019
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N16 (500 mg/150 mg)	PVC/Al blister		15-0014-03	Labelling text Aug 15, 2019
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N20 (500 mg/150 mg)	PVC/Al blister		15-0014-04	Labelling text Aug 15, 2019
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N24 (500 mg/150 mg)	PVC/Al blister		15-0014-05	Labelling text Aug 15, 2019
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N30 (500 mg/150 mg)	PVC/Al blister		15-0014-06	Labelling text Aug 15, 2019
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N32 (500 mg/150 mg)	PVC/Al blister		15-0014-07	Labelling text Aug 15, 2019

Registration information

Marketing authorisation No.	15-0014
Date of authorisation	Jan 27, 2015
Marketing authorisation holder, country	Swixx Biopharma Kft, Hungary

Return to the results

Icon explanation

– Medicine is available
– Medicine is not available
– Distribution permitted for a limited time span
– Without a prescription
– Prescription medicine

– Medicine is listed on the Latvian National Health Service (NHS) list of state reimbursed medicines. (source of the information – the NHS)
– Reference medicine on the NHS List of state reimbursed medicines
– Lowest cost medicine within its therapeutic effectiveness class in cases where no reference medicine is available
- – Next lowest cost medicine after or (in ascending order)

Class A A (green): Suitable for the older persons. The medicinal substance can be used as in younger patients. Changes due to aging do not affect the dose or frequency of administration, and the adverse reaction profile is not different from that of younger patients.

Class B B (grey): There is little research evidence, practical experience or efficacy in older persons.

Class C C (yellow): Suitable for older persons, with specific cautions. The medicinal substance can be used by older persons, but the dose might either have to be reduced, or the frequency of administration decreased due to mild or moderate renal insufficiency or a significant risk of interactions or adverse reactions.

Class D D (red): Avoid use in older persons. Use is possible only in exceptional cases or on a one-off basis. Changes due to aging predispose older persons to adverse or dangerous reactions to the drug. The risk of adverse reactions typically exceeds the benefits.

Meds75+ data source is Finnish Medicines Agency Fimea (licensed under CC BY 4.0).
Data updated on Apr 22, 2024.